Thousands of men living with advanced, hormone-sensitive prostate cancer (HSPC) in England and Wales will be able to access Bayer's Nubeqa, after it was recommended for NHS use by reimbursement ...

An injectable form of HIV pre-exposure prophylaxis (PrEP) developed by GSK's ViiV Healthcare unit will be offered by the NHS in England and Wales, ending a disparity in access within the UK.